Precision Revenue Intelligence & Precision Care — for labs, specialty practices & value-based care
Ardia builds governed, auditable AI — the TARA reasoning core and a constellation of specialised models — for the jobs that drain labs and care teams: recovering wrongly denied lab revenue, modelling the 2027 PAMA cliff, and supporting precision medicine, pulmonary and elder care. Pre-revenue, seed-stage — every figure is measured, cited, or a modelled target.
We're not a billing software. We're not an alert system. We're a clinical reasoning engine that understands payer logic from the inside.
Our engine reads clinical documentation, cross-references payer-specific LCD rules, and generates a mechanistic explanation for every denial — then builds the evidence-backed recovery argument.
Engineering and operating roles inside Cigna, UnitedHealth Group, Optum, Teladoc, Interwell Health and ECFMG. We've built within the payer systems that construct coverage and denial decisions — so we know the adjudication logic from the inside, and exactly how to reverse it.
We earn 15–20% of recovered revenue only when you succeed. No upfront cost. No implementation fees. ROI is designed to surface within ~30 days of deployment — a modelled target, pre-pilot.
Manual appeals cost $118 and succeed 45% of the time on average — industry benchmarks (Change Healthcare 2023, HFMA 2024). Ardia automates that costly manual process end-to-end: grounded in policy and the patient record, with practitioner review before submission.
The only platform combining genomic intelligence with reimbursement intelligence. We make precision medicine economically sustainable — MolDX, Z-codes, and 400+ PLA codes.
Planned under BAA: HIPAA-eligible GCP services — Vertex AI, Cloud Healthcare API (FHIR R4), BigQuery, Cloud Run. Target: US data residency (us-central1), AES-256 at rest, TLS 1.3 in transit. The current prototype runs on Vercel + Anthropic Claude.
The areas Ardia is focused on today — click any card to go deep. Pre-revenue; every figure is measured, cited, or a modelled target.
AI for the aging population — Aria (voice companion, red-flag safety check, 911 escalation) and Cadence, the trained movement model (95.45% held-out on public UCI HAR data), plus the elder-care modules.
Explore →Longitudinal asthma & COPD intelligence — aligned to GOLD and GINA staging concepts (guideline retrieval corpus in development), with pulmonary-function and sleep-study coding integrity. Decision-support, non-diagnostic.
Explore →A deterministic, in-browser model of the 2027–2029 CLFS cuts and the exact revenue at risk for your test mix. No PHI; the compounding math is unit-tested.
Explore →Personalise each patient's care — the right drug & dose (pharmacogenomics), therapy matched to the molecular target, inherited risk caught early. Plus the access layer that gets the enabling tests covered.
Explore →Policy-grounded, cited denial appeals for toxicology & molecular billing — G0480–G0483, NCCI edits, CARC/RARC. Drafts for a human to review and submit.
Explore →Every model and agent in one place — Lumen, Aria, MolecuIQ, ToxIQ, PulmoIQ, Cadence, TARA, Meridian, Sentinel — each with its AI engine, frameworks, and honest status.
Explore →A quick tour of the governed models and the Ardia One care hub — de-identified inputs, cite-or-abstain answers, and a unified elder-first experience. Synthetic data; Ardia is pre-revenue.
Illustrative walkthrough on synthetic data — not a diagnosis, and not real patient information.
Nine named models and agents — each does one job well, all share one governed core (TARA reasoning + Sentinel de-identification). Click any to watch it reason through a real case. Pre-revenue: every status is measured, cited, or a modelled target.
A voice-first companion for older adults — daily check-ins, medication support, a red-flag safety check (stroke FAST, suicide C-SSRS), and 911 escalation. Talks in real time; never diagnoses.
Turns a lab report or scan into plain language a patient can act on — flags what stands out, names what to confirm, explains options. De-identified first by Sentinel. Non-diagnostic.
Reads a denied molecular/genomic claim and drafts a cited appeal — NGS panels (81445/81455), MolDX Z-codes, CO-50 medical-necessity. A human reviews and submits; never auto-filed.
Turns a denied toxicology claim into a policy-cited appeal — G0480–G0483, NCCI edits, CARC/RARC — with a PGx overlay explaining unexpected negative screens. Drafted for a human to submit.
Builds a longitudinal asthma/COPD picture against GOLD & GINA and supports PFT and sleep-study reimbursement. Anything that predicts disease stays behind FDA clearance.
The Triadic Adjudicative Reasoning core every agent runs on — a deterministic policy engine plus a guarded LLM that cannot override policy or safety. Always human-in-the-loop, always auditable.
The one genuinely trained & measured model — senses the earliest drop in daily movement from a phone. 95.45% held-out on public UCI HAR, subject-independent. Not a fall detector.
A deterministic, in-browser model of the 2027–2029 PAMA rate cliff — enter a test mix and watch the revenue at risk compound. No PHI, no server; the math is unit-tested.
The compliance kernel — de-identifies every record to HIPAA Safe Harbor before any agent runs, and logs a tamper-evident audit trail. A guardrail the others depend on, not a feature.
The RCM space is crowded with alerting tools, billing software, and generic AI. Ardia is the only platform that reasons, argues, and proves — built by people who designed the denial systems it defeats.
| Capability | Quest / LabCorp RCM | Generic AI (Olive, Waystar) | Traditional RCM Vendors | ⚡ Ardia Precision Health ✓ = designed / in build, not yet shipped |
|---|---|---|---|---|
| Clinical Reasoning (not just flagging) | ✗ | ✗ | ✗ | ✓ |
| Lab-Specific Denial Logic (LCD/NCD) | ⚠ Partial |
✗ | ✗ | ✓ |
| Auto-Generated Appeal Narratives | ✗ | ⚠ Generic only |
✗ | ✓ |
| Pharmacogenomics + MolDX Reimbursement | ✗ | ✗ | ✗ | ✓ |
| Zero-Risk Contingency Pricing | ✗ | ✗ | ⚠ Rare |
✓ |
| TX SB 1188 + TRAIGA Compliant by Design | ✗ | ✗ | ✗ | ✓ |
| Built by Former Payer Insiders (Cigna/UHC) | ✗ | ✗ | ✗ | ✓ |
Six decision-support steps, each reviewed by a licensed professional before anything is submitted. No template letters. Clinical reasoning powered by AI at every stage — from raw denial data to a payer-formatted appeal draft — a design target of under 90 seconds per claim.
The AI in RCM market grows at 24% CAGR. Independent labs are completely unserved.
Precision medicine uses a patient's own genomic and molecular profile to personalise prevention and treatment — the right drug and dose, therapy matched to a tumour's biology, and inherited risk caught early. Ardia is building the decision-support for that, and the access layer (MolecuIQ, today) that gets the enabling tests covered so cost isn't what blocks a patient.
Flags pathogenic hereditary variants — BRCA1/2, Lynch — with ACMG classification, then points to personalised screening, risk-reducing prevention and family cascade testing. Preventing disease, not only treating it.
Reads the patient's own pharmacogenomics — CYP2C19, CYP2D6, DPYD, TPMT, HLA-B — to flag drug–gene risks and guide a safer choice and dose (CPIC), avoiding adverse reactions and medications that won't work for them. Non-diagnostic decision-support.
Interprets a tumour's molecular profile — EGFR, ALK, BRAF, KRAS, MSI-H/TMB — and surfaces NCCN-guideline targeted therapies, immunotherapy and open trials to support the oncologist's personalised plan.
Brings genomic, molecular, clinical and lifestyle signals into one evolving, personalised risk-and-prevention view — including liquid-biopsy and ctDNA monitoring for earlier detection and response tracking.
Coverage and clinical-guideline policies (CPIC, NCCN, LCD/NCD, MolDX) are encoded as deterministic rules, so every recommendation traces to a named source rather than a black box. Being built.
MolDX/Z-code validation, medical-necessity documentation and cited appeals get the enabling molecular test paid — the plumbing that makes the personalised answer reachable. MolecuIQ drafts; a human reviews and submits.
The models we're building today — across lab reimbursement (ToxIQ, MolecuIQ), precision medicine (genomics & pharmacogenomics), the PAMA rate cliff (Meridian), pulmonary care (PulmoIQ), elder care (Aria + Cadence), and plain-language reports (Lumen) — each running on the TARA reasoning core and the Sentinel compliance kernel.
Explore how Ardia's models reason over denials — policy matching, MAC LCD cross-reference, and evidence-backed appeal drafting. A mobile companion is on the roadmap.
Ardia Precision Health, Inc. · ardiahealthlabs.com · info@ardiahealthlabs.com · Pre-Revenue · Seed Stage · Building on Google Cloud
Two founders who engineered and operated inside the payer systems Ardia is built to navigate — with a CEO driving strategy, partnerships and growth across precision medicine, molecular diagnostics, the PAMA rate cliff, pulmonary care and elder care.
Creator of the TARA reasoning framework. 15+ years in enterprise IT with 9+ in healthcare engineering — Software Engineering Lead at Cigna, Senior SDE at Teladoc, Senior Software Developer at ECFMG, plus UnitedHealth Group / Optum — building inside the payer systems that generate denials.
10+ years across UnitedHealth Group, Interwell Health and ECFMG — inside the payer and health-services operations that decide coverage and manage care. She grounds Ardia’s product direction and go-to-market in real-world clinical and reimbursement workflows.
A practicing veterinary doctor, Paramesh leads business strategy, go-to-market, partnerships and investor relations — bringing a clinical and scientific lens to how Ardia builds governed, non-diagnostic AI for healthcare.
Board: Sireesha Mamillapalli, Ph.D. — Assistant Professor of Biochemistry & Physiology, Geisinger Commonwealth School of Medicine, bringing scientific rigor to our validation methodology. · Full team & story →
Concept: interactive dashboard showing a modelled denial analysis, MAC LCD cross-reference, and recovery narrative generation.
